Tesevatinib is primarily investigated for its potential in treating various types of cancer, particularly those driven by specific genetic mutations. It is being studied in clinical trials for its efficacy in targeting cancers such as non-small cell lung cancer (NSCLC), where it may inhibit the growth of tumors by blocking certain tyrosine kinases involved in cancer progression. Additionally, tesevatinib is being explored for its use in treating polycystic kidney disease (PKD) due to its ability to modulate signaling pathways that contribute to cyst formation and growth. Its application in these areas highlights its potential as a therapeutic agent in both oncology and genetic disorders.